COMPOSITION FOR PRESERVING PLATELETS AND METHOD OF USING AND STORING THE SAME

• US 20100221697A1
• Filed: 04/29/2010
• Published: 09/02/2010
• Est. Priority Date: 01/12/2005
• Status: Abandoned Application

• Current Assignee: Biovec Transfusion LLC
• Original Assignee: Biovec Transfusion LLC
• Inventors: SEHGAL, Lakshman R.
• Application Number:
  US12/770,389
• Publication Number:
  US 20100221697A1
• Time in Patent Office: Days
• US Class Current: 435/2
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
• CPC Class Codes: A01N 1/0284 Temperature processes, i.e. using a designated change in temperature over time
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

The present invention relates to a method for preserving and storing platelets. The method includes the steps of admixing inactivated, functional platelets with a preservative composition comprising an effective amount of one or more pharmaceutically acceptable inhibitors of platelet activation to form preserved platelets, storing the preserved platelets at low temperature, and removing the one or more inhibitors of platelet activation from the preserved platelets by diafiltration prior to transfusion.

Claims

1. A method for preserving platelets, comprising:

admixing inactivated, functional platelets with a preservative composition comprising an effective amount of one or more pharmaceutically acceptable inhibitors of platelet activation to form preserved platelets;

storing the preserved platelets at a low temperature; and

removing the one or more inhibitors of platelet activation from the preserved platelets by diafiltration prior to transfusion,

wherein said low temperature is in the range of about −

20°

C. to 12°

C.

2. The method of claim 1, wherein said one or more inhibitors of platelet activation comprise an anticoagulant and an antiplatelet agent.

3. The method of claim 2, wherein said antiplatelet agent is capable of binding to, or associating with a GPIIb/IIIa receptor site.

4. The method of claim 2, wherein said antiplatelet agent is selected from the group consisting of DUP728, XJ757, XR299, eptifibatide, orbofiban, xemilofiban, Lamifiban, tirofiban (Aggrastat), and mixtures thereof.

5. The method of claim 2, wherein said antiplatelet agent is selected from the group consisting of linear and cyclic RGD analogs.

6. The method of claim 5, wherein said linear and cyclic RGD analogs are conjugated to a nitric oxide donor.

7. The method of claim 2, wherein said antiplatelet agent has a circulating half-life of inhibition of about less than 4 hours.

8. The method of claim 2, wherein said antiplatelet agent comprises GPIIb/IIIa inhibitor at a concentration of about 0.2 μ

g/ml to about 0.1 mg/ml.

9. The method of claim 2, wherein said antiplatelet agent comprises GPIIb/IIIa inhibitor at a concentration of about 10 μ

g/ml to about 60 μ

g/ml.

10. The method of claim 2, wherein said anticoagulant is a compound that reversibly inhibits factor Xa, or factor IIa, or both.

11. The method of claim 10, wherein said anticoagulant is a short-to-ultrashort acting Xa inhibitor with a circulating half-life of less than 4 hours.

12. The method of claim 10, wherein said anticoagulant is selected from the group consisting of DX-9065a, BX-80783, RPR-120844, and short-to-ultrashort acting Xa inhibitors.

13. The method of claim 10, wherein said anticoagulant is a short-to-ultrashort acting IIa inhibitor selected from the group consisting of hirudin, hirulog, melgatran, and combinations thereof.

14. The method of claim 10, wherein said anticoagulant is a combination of at least one short-to-ultrashort acting IIa inhibitor, and at least one short-to-ultrashort acting Xa inhibitor.

15. The method of claim 2, wherein said antiplatelet agent is a compound that binds to or associates with GPIIb/IIIa sites, and wherein the anticoagulant is a factor Xa inhibitor, a factor IIa inhibitor, or a combination of both.

16. The method of claim 1, wherein said preservative composition further comprises an oxygen carrier.

17. The method of claim 16, wherein said oxygen carrier is selected from the group consisting of hemoglobin, ferroprotoporphyrin, perfluorochemicals, and mixtures thereof.

18. The method of claim 17, wherein said oxygen carrier is a hemoglobin-based oxygen carrier.

19. The method of claim 18, wherein said hemoglobin-based oxygen carrier is substantially free of red cell membrane contaminants.

20. The method of claim 16, wherein said mixture is stored in an oxygen-permeable bag.

21. The method of claim 16, wherein said mixture is stored in an oxygen-impermeable bag.

22. The method of claim 1, wherein said preservative composition further comprises a short-to-ultrashort acting broad spectrum anti-microbial agent selected from the group consisting of:

Penicillin, Natural penicillins, Semisynthetic penicillins, Monobactam, Cephalosporin Carbapenems Vancomycin, Isoniazid (INH), Ethambutol, Aminoglycoside, Tetracycline, Chloramphenicol, Macrolide, Rifamycin, Quinolone, Fluoroquinolone, Sulfonamide, Synergism, Polyene antibiotic, Imidazole, Triazole, Griseofulvin and combinations thereof.

23. The method of claim 1, wherein said low temperature is in the range of about 0°

C. to about 12°

C.

24. The method of claim 1, wherein said low temperature is in the range of about 4°

C. to about 12°

C.

25. The method of claim 1, wherein said low temperature is in the range of about 4°

C. to about 8°

C.